Payment overview · 2025
General Payments
$369.10
20 reported records · 8 companies
Healthcare provider profile · identity verified
Bryan C Bunn, MD
Allopathic & Osteopathic Physicians|Family Medicine · EDENTON, NC · NPI 1568787141
Verified facts
What the public records show
CMS Open Payments records show Bryan C Bunn, MD received $369.10 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synjardy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $126.30 | 34.2% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.28 | 14.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.52 | 12.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.56 | 11.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.19 | 9.8% | 2 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $35.69 | 9.7% | 1 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $15.50 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.06 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $369.10 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.68 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.68 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.52 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.56 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.56 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.07 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| EXOGEN ULTRASOUND BONE HEALING SYSTEM Normalized: exogen ultrasound bone healing system |
Device | Bioventus LLC | $35.69 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.59 | 2 | 2025 |
Source payment records
|
|||||
| MONOVISC Normalized: monovisc |
Device | DePuy Synthes Sales Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| ORTHOVISC Normalized: orthovisc |
Device | DePuy Synthes Sales Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 188 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 131 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
89 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
188 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 710 | 175 |
| Amlodipine Besylate | Amlodipine Besylate | 569 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 447 | 94 |
| Omeprazole | Omeprazole | 354 | 91 |
| Gabapentin | Gabapentin | 351 | 90 |
| Losartan Potassium | Losartan Potassium | 275 | 75 |
| Pravastatin Sodium | Pravastatin Sodium | 250 | 58 |
| Lisinopril | Lisinopril | 249 | 62 |
| Meloxicam | Meloxicam | 233 | 56 |
| Celecoxib | Celecoxib | 225 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 224 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 220 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 54 |
| Metformin Hcl Er | Metformin Hcl | 219 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 204 | 65 |
| Allopurinol | Allopurinol | 199 | 45 |
| Trazodone Hcl | Trazodone Hcl | 195 | 51 |
| Eliquis | Apixaban | 188 | 36 |
| Furosemide | Furosemide | 183 | 59 |
| Tramadol Hcl | Tramadol Hcl | 183 | 31 |
| Famotidine | Famotidine | 166 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 44 |
| Carvedilol | Carvedilol | 165 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 162 | 52 |
| Valsartan | Valsartan | 158 | 41 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 155 | 36 |
| Atenolol | Atenolol | 150 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 60 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 144 | 38 |
| Jardiance | Empagliflozin | 131 | 27 |
| Potassium Chloride | Potassium Chloride | 130 | 29 |
| Metformin Hcl | Metformin Hcl | 124 | 30 |
| Chlorthalidone | Chlorthalidone | 119 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 30 |
| Lorazepam | Lorazepam | 118 | 16 |
| Spironolactone | Spironolactone | 111 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 106 | 26 |
| Simvastatin | Simvastatin | 104 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 24 |
| Montelukast Sodium | Montelukast Sodium | 95 | 27 |
| Mirtazapine | Mirtazapine | 94 | 14 |
| Ozempic | Semaglutide | 94 | 16 |
| Alprazolam | Alprazolam | 91 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 31 |
| Synthroid | Levothyroxine Sodium | 89 | 15 |
| Pregabalin | Pregabalin | 87 | 17 |
| Prednisone | Prednisone | 86 | 37 |
| Bupropion Xl | Bupropion Hcl | 83 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 78 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 23 |
| Trulicity | Dulaglutide | 77 | 14 |
| Finasteride | Finasteride | 76 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 76 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | 19 |
| Xarelto | Rivaroxaban | 72 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 13 |
| Irbesartan | Irbesartan | 62 | 13 |
| Myrbetriq | Mirabegron | 62 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 14 |
| Sertraline Hcl | Sertraline Hcl | 58 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 52 | 11 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 48 | suppressed |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Diazepam | Diazepam | 46 | suppressed |
| Temazepam | Temazepam | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 19 |
| Eszopiclone | Eszopiclone | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 21 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Glimepiride | Glimepiride | 42 | 12 |
| Glipizide | Glipizide | 41 | 12 |
| Telmisartan | Telmisartan | 41 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 40 | suppressed |
| Sucralfate | Sucralfate | 40 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 33 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 15 |
| Sotalol | Sotalol Hcl | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Belsomra | Suvorexant | 30 | suppressed |
| Clonidine | Clonidine | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Nateglinide | Nateglinide | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Klor-Con M10 | Potassium Chloride | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Indomethacin | Indomethacin | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 21 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | 12 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Naproxen | Naproxen | 17 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $369.10 · 20 records | Novo Nordisk Inc | ELIQUIS, EXOGEN ULTRASOUND BONE HEALING SYSTEM, JARDIANCE, LEQVIO, MONOVISC, NURTEC ODT, ORTHOVISC, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, Wegovy, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error